Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U-DANCE-anti-AML WT1 cord blood-derived dendritic cell vaccination trial
NL-OMON27248Phase 2Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2016
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 CBDC vaccine in acute myeloid leukemia (AML), sponsored by University Medical Center Utrecht. Primary endpoints: Dose-limiting toxicity including acute graft-versus-host disease and One-year relapse-free survival. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
WT1 CBDC vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON27248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27248.